Study of LaNova Medicines(LM)-302 in Combination With Toripalimab in Patients With Advanced Solid Tumors
A Phase I/II, Open-Label, Multiple Centre Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Preliminary Efficacy of LM- 302 in Combination with Toripalimab in Patients with Advanced Solid Tumors
Advanced Solid Tumor
DRUG: LM-302|DRUG: Toripalimab
DLT, To assess the safety and tolerability for LM-302 in combination with toripalimab in subjects with advanced solid tumors., Cycle 1 of each cohort. Duration of one cycle is 21 days|RP2D, Obtain the recommended phase 2 dose (RP2D) for LM-302 in combination with toripalimab in subjects with advanced solid tumors., Up to 6 months|OBD, Obtain the optimal biologic dose (OBD) for LM-302 in combination with toripalimab in subjects with advanced solid tumors., Up to 6 months|MTD, Obtain the Maximum Tolerated Dose (MTD) for LM-302 in combination with toripalimab in subjects with advanced solid tumors., Up to 21 days
This is a study of LM-302 in combination with toripalimab in patients with advanced solid tumors .The study includes phase I (dose escalation) and phase II (dose expansion). All participants enrolled in the study will be administered every 3 weeks (1 cycle=21 days) with a dose of LM-302 intravenous infusion followed by toripalimab intravenous infusion on day 1 until meet the criteria of treatment discontinuation or withdraw, whichever occurs earlier.